Qiu-ping Xiang

发表

ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer

K. Lam, Yan Zhang, Yong Xu, 2016, Nature Medicine.

Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer.

Yan Zhang, Yong Xu, C. Zhang, 2018, ACS medicinal chemistry letters.

Discovery, optimization and evaluation of 1-(indolin-1-yl)ethan-1-ones as novel selective TRIM24/BRPF1 bromodomain inhibitors.

Yan Zhang, Yong Xu, Qiu-ping Xiang, 2022, European journal of medicinal chemistry.

CBP/p300 bromodomain: new promising epigenetic target

Yan Zhang, Yong Xu, Qiu-ping Xiang, 2022, Visualized Cancer Medicine.

Structural insights revealed by the cocrystal structure of CCS1477 in complex with CBP bromodomain.

Yan Zhang, Qiu-ping Xiang, Yong Xu, 2022, Biochemical and biophysical research communications.

Design, synthesis and pharmacological characterization of N-(3-ethylbenzo[d]isoxazol-5-yl) sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia

Yan Zhang, Xiao-yu Luo, Yong Xu, 2022, Acta Pharmacologica Sinica.

Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.

Yan Zhang, Donghai Wu, Benqiang Yao, 2022, Journal of medicinal chemistry.

Discovery and optimization of novel N-benzyl-3,6-dimethylbenzo[d]isoxazol-5-amine derivatives as potent and selective TRIM24 bromodomain inhibitors with potential anti-cancer activities.

Yan Zhang, Yong Xu, Donghai Wu, 2019, Bioorganic chemistry.

Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer

Yan Zhang, Yong Xu, Qiu-ping Xiang, 2019, Acta Pharmacologica Sinica.

Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC).

Yan Zhang, Yong Xu, Donghai Wu, 2018, Journal of medicinal chemistry.

2-Amino-2,3-dihydro-1H-indene-5-carboxamide-Based Discoidin Domain Receptor 1 (DDR1) Inhibitors: Design, Synthesis, and in Vivo Antipancreatic Cancer Efficacy

A. Bullock, R. Brekken, Xiaoyun Lu, 2019, Journal of medicinal chemistry.

Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer.

Yan Zhang, Yong Xu, Guohui Li, 2018, European journal of medicinal chemistry.

Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.

Yan Zhang, Yong Xu, X. Kong, 2021, Journal of medicinal chemistry.

Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.

Yan Zhang, Ke Ding, Yong Xu, 2016, Journal of medicinal chemistry.

Y06014 is a selective BET inhibitor for the treatment of prostate cancer

Yan Zhang, Yong Xu, Qiu-ping Xiang, 2021, Acta Pharmacologica Sinica.

Rational design, synthesis and biological evaluation of benzo[d]isoxazole derivatives as potent BET bivalent inhibitors for potential treatment of prostate cancer.

Yan Zhang, Yong Xu, Qiu-ping Xiang, 2023, Bioorganic chemistry.

Design, Synthesis, and Biological Evaluation of 3-(Imidazo[1,2-a]pyrazin-3-ylethynyl)-4-isopropyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide as a Dual Inhibitor of Discoidin Domain Receptors 1 and 2

A. Bullock, R. Brekken, Tingting Xu, 2018, Journal of medicinal chemistry.

Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.

Cheng Zhang, Ke Ding, Donghai Wu, 2018, European journal of medicinal chemistry.

Discovery and Characterization of Benzimidazole Derivative XY123 as a Potent, Selective, and Orally Available RORγ Inverse Agonist.

Yan Zhang, Yong Xu, Donghai Wu, 2021, Journal of medicinal chemistry.

Discovery of a potent and selective CBP bromodomain inhibitor (Y08262) for treating acute myeloid leukemia

Yan Zhang, Qiu-ping Xiang, Tian Wu, 2023, Bioorganic Chemistry.

Trends in Research on Traditional Chinese Health Exercises for Improving Cognitive Function: A Bibliometric Analysis of the Literature From 2001 to 2020

Qiu-ping Xiang, Linman Weng, Wenlong Li, 2022, Frontiers in Public Health.

Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer

Yan Zhang, Yong Xu, Qiu-ping Xiang, 2019, Acta Pharmacologica Sinica.